Products | PC | phaseⅠ | phaseⅡ | phaseⅢ |
---|---|---|---|---|
NC-6004 Cisplatin micelle |
||||
Head and Neck cancer(EU/Taiwan)
Combination therapy with Kyet ruda® |
||||
Co-Development Partner:Orient Europharma(Taiwan) |
||||
NC-6300 Epirubicin micelle |
||||
Soft tissue sarcoma(USA)
|
||||
In-House Development FDA Orphan drug designation |
||||
SRN-14/GL2-800 (PRDM14 siRNA) |
||||
HER2-negative breast cancer (Japan)
|
||||
Investigator-initiated | ||||
TUG1 ASO | ||||
GBM (Japan)
|
||||
Collaboration with NAGOYA University | ||||
NK105 Paclitaxel micelle (Out-Licensed) |
||||
Breast cancer(Japan/Asia)
|
||||
Out-licensed to Nippon Kayaku(Aria:Japan/Asia) |
Products | PC | phaseⅠ | phaseⅡ | phaseⅢ | Marketing |
---|---|---|---|---|---|
VB-111 Non-replicating Adeno 5 vector |
|||||
Ovarian cancer(USA/Israel/EU/Japan)
Combination therapy with Paclitaxel |
|||||
Co-Development Partner:VBL(Israel) |
|||||
rGBM
|
|||||
Investigator-initiated(USA) | |||||
Colorectal Cancer
|
|||||
Operation by NCI/VBL(USA) | |||||
ENT103 ENT product |
|||||
Otitis media(Japan)
|
|||||
Co-Development Partner:CEOLIA PHARMA(Japan) |
|||||
Aeon Acti-PRP Regenerative medicine |
|||||
Intractable infertility PRP therapy(Japan)
|
|||||
Distributor |